Related Experiment Video
Updated: Jan 14, 2026

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy
Chengqian Chen1, Wei Guo1, Haotian Wang1
1Department of Hematology,The First Hospital of Jilin University, Changchun, China.
Abstract:
Diffuse large B-cell lymphoma and follicular lymphoma exhibit complex metabolic and immune microenvironments that influence disease progression and treatment response. Metabolic reprogramming, including glycolysis, amino acid, and lipid metabolism, supports tumor growth while suppressing anti-tumor immunity. Immune components such as tumor-infiltrating lymphocytes and checkpoint molecules (PD-L1, LAG-3, TIM-3) further modulate prognosis. Elevated tumor metabolic volume and glycolytic activity correlate with aggressive disease and poor outcomes. Conversely, high TIL density often predicts better responses. Integrating metabolic and immune biomarkers enhances risk stratification and therapeutic strategies, highlighting the potential for combined metabolic inhibitors and immunotherapies to improve precision medicine in lymphoma.
Related Concept Videos
The Tumor Microenvironment
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

